- Dual targeting of acetylcholinesterase and tau aggregation: Design, synthesis and evaluation of multifunctional deoxyvasicinone analogues for Alzheimer's disease
-
Development of multitargeted ligands have demonstrated remarkable efficiency as potential therapeutics for Alzheimer's disease (AD). Herein, we reported a new series of deoxyvasicinone analogues as dual inhibitor of acetylcholinesterase (AChE) and tau aggregation that function as multitargeted ligands for AD. All the multitargeted ligands 11(a-j) and 15(a-g) were designed, synthesized, and validated by 1HNMR, 13CNMR and mass spectrometry. All the synthesized compounds 11(a-j) and 15(a-g) were screened for their ability to inhibit AChE, BACE1, amyloid fibrillation, α-syn aggregation, and tau aggregation. All the screened compounds possessed weak inhibition of BACE-1, Aβ42 and α-syn aggregation. However, several compounds were identified as potential hits in the AChE inhibitory screening assay and cellular tau aggregation screening. Among all compounds, 11f remarkably inhibited AChE activity and cellular tau oligomerization at single-dose screening (10 μM). Moreover, 11f displayed a half-maximal inhibitory concentration (IC50) value of 0.91 ± 0.05 μM and half-maximal effective concentration (EC50) value of 3.83 ± 0.51 μM for the inhibition of AChE and cellular tau oligomerization, respectively. In addition, the neuroprotective effect of 11f was determined in tau-expressing SH-SY5Y cells incubated with Aβ oligomers. These findings highlighted the potential of 11f to function as a multifunctional ligand for the development of promising anti-AD drugs.
- Manzoor, Shoaib,Gabr, Moustafa T.,Rasool, Bisma,Pal, Kavita,Hoda, Nasimul
-
-
- TRICYCLIC COMPOUNDS
-
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers or congenital diseases. Specific cancers and congenital disease includes those that are mediated by YAP/TAZ.
- -
-
Paragraph 00282
(2017/08/01)
-
- Triazinone compound and T-type calcium channel inhibitor
-
There is provided a novel triazinone compound that has an excellent T-type voltage-dependent calcium channel inhibitory activity and is specifically useful for treatment of pain. A compound of Formula (I), a tautomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof: where each substituent is defined in detail in the description or claims, for example R1 is H or C1-6 alkoxy, etc., each of L1 and L2 is independently a single bond or NR2, etc., L3 is C1-6 alkylene, etc., A is C6-14 aryl or 5 to 10-membered heteroaryl which is optionally substituted, etc., B is C3-11 cycloalkylene, etc., D is C6-14 aryl or 5 to 10-membered heteroaryl which is optionally substituted, etc.
- -
-
Page/Page column 82
(2016/08/29)
-
- HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE
-
The present invention provides a novel hydroxyquinoxaline carboxamide derivative that is useful for preventing and/or treating blood coagulation disorders. A compound represented by formula (i), or a pharmacologically acceptable salt thereof: wherein, each of R1 and R2 independently represents a group such as a hydrogen atom or a halogen atom; R3 represents a group such as a hydrogen atom; each of R4 and R5 independently represents a group such as a hydrogen atom, a halogen atom or a C1-4 alkyl group; each of R6 and R7 independently represents a hydrogen atom or a C1-4 alkyl group; X represents a group such as a C3-10 cycloalkyl group, C6-10 aryl group or a 5- to 10-membered heterocyclic group, which may be substituted with substituent(s) selected from substituent group α; Y represents a group such as -CO-, -O- or -NRa-, and Ra represents a group such as a hydrogen atom or a C1-4 alkyl group.
- -
-
Page/Page column 50
(2010/12/29)
-
- Discovery of N-(3-fluorophenyl)-1-[(4-([(35)-3-methyl-1-piperazinyl]methyl) phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate
-
N-(3-Fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl) acetyl]-4-piperidinamine 12 (GSK962040) is a novel small molecule motilin receptor agonist. It possesses excellent activity at the recombinant human motilin receptor and also at the native rabbit motilin receptor where its agonist activity results in potentiation of the amplitude of neuronal-mediated contractions of isolated gastric antrum tissue. Compound 12 also possesses highly promising pharmacokinetic profiles in both rat and dog, and these results, in combination with further profiling in human native tissue and an in vivo model of gastrointestinal transit in the rabbit, have led to its selection as a candidate for further development.
- Westaway, Susan M.,Brown, Samantha L.,Fell, Stephen C. M.,Johnson, Christopher N.,MacPherson, David T.,Mitchell, Darren J.,Myatt, James W.,Stanway, Steven J.,Seal, Jon T.,Stemp, Geoffrey,Thompson, Mervyn,Lawless, Kirk,McKay, Fiona,Muir, Alison I.,Barford, Jonathan M.,Cluff, Chermaine,Mahmood, Sadhia R.,Matthews, Kim L.,Mohamed, Shiyam,Smith, Beverley,Stevens, Alexander J.,Bolton, Victoria J.,Jarvie, Emma M.,Sanger, Gareth J.
-
experimental part
p. 1180 - 1189
(2010/01/16)
-
- Piperazine Heteroaryl Derivatives as Gpr38 Agonists
-
The invention provides compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, Z, X and B are as defined in the specification. The compounds are partial or full agonists at the GPR38 receptor. Pharmaceutical compositions comprising the compounds, methods of preparing the compounds, uses of the compounds and methods involving the compounds are also provided.
- -
-
Page/Page column 14
(2009/01/24)
-
- The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor
-
Optimisation of urea (5), identified from high throughput screening and subsequent array chemistry, has resulted in the identification of pyridine carboxamide (33) which is a potent motilin receptor agonist possessing favourable physicochemical and ADME profiles. Compound (33) has demonstrated prokinetic-like activity both in vitro and in vivo in the rabbit and therefore represents a promising novel small molecule motilin receptor agonist for further evaluation as a gastroprokinetic agent.
- Westaway, Susan M.,Brown, Samantha L.,Conway, Elizabeth,Heightman, Tom D.,Johnson, Christopher N.,Lapsley, Kate,Macdonald, Gregor J.,MacPherson, David T.,Mitchell, Darren J.,Myatt, James W.,Seal, Jon T.,Stanway, Steven J.,Stemp, Geoffrey,Thompson, Mervyn,Celestini, Paolo,Colombo, Andrea,Consonni, Alessandra,Gagliardi, Stefania,Riccaboni, Mauro,Ronzoni, Silvano,Briggs, Michael A.,Matthews, Kim L.,Stevens, Alexander J.,Bolton, Victoria J.,Boyfield, Izzy,Jarvie, Emma M.,Stratton, Sharon C.,Sanger, Gareth J.
-
scheme or table
p. 6429 - 6436
(2009/09/06)
-
- BIARYL COMPOUNDS USEFUL AS AGONISTS OF THE GPR38 RECEPTOR
-
The present invention relates to novel biaryl derivatives such as compounds of formula (I), which have activity as agonists of the GPR38 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of gastrointestinal dis
- -
-
Page/Page column 25
(2008/06/13)
-
- COMPOUNDS
-
The present invention relates to novel benzylpiperazine derivatives such as compounds of formula (I), which have activity as agonists of the GPR38 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of gastrointestinal disorders.
- -
-
Page/Page column 31
(2008/06/13)
-
- PIPERAZINE HETEROARYL DERIVATES AS GPR38 AGONISTS
-
The invention provides compounds of formula (I) or pharmaceutically acceptable salts thereof, (I) wherein R1, R2, R3, R4, R5, R6, Z, X and B are as defined in the specification. The compounds are partial or full agonists at the GPR38 receptor. Pharmaceutical compositions comprising the compounds, methods of preparing the compounds, uses of the compounds and methods involving the compounds are also provided.
- -
-
Page/Page column 42
(2010/11/25)
-
- BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS
-
The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions or disorders which are mediated via the GPR38 receptor.
- -
-
Page/Page column 25
(2008/06/13)
-
- Cyclic amine compounds and pharmaceutical composition containing the same
-
A cyclic amine compound represented by the following general formula (1): wherein, R1, R2 and R3 each independently represent a hydrogen atom or an alkoxy group;W1 and W2 each independently represent N or CH;X represents O, NR4, CONR4 or NR4CO;R4 represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; andl, m and n each represents a number of 0 or 1, a salt thereof and a hydrate thereof are provided. These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.
- -
-
-
- PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES
-
The present invention relates to compounds of the general formula (I) wherein R1 is lower alkyl, -(CH2)n-aryl, unsubstituted or substituted by one or two substituents, selected from the group consisting of lower alkyl, low
- -
-
-
- Cyclic amine compounds and pharmaceutical composition containing the same
-
A cyclic amine compound represented by the following general formula (1): wherein, R1, R2 and R3 each independently represent a hydrogen atom or an alkoxy group; W1 and W2 each independently represent N or CH; X represents O, NR4, CONR4 or NR4CO; R4 represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; and l, m and n each represents a number of 0 or 1, a salt thereof and a hydrate thereof are provided. These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.
- -
-
-
- First dual NK1 antagonists-serotonin reuptake inhibitors: Synthesis and SAR of a new class of potential antidepressants
-
Compounds combining NK1 antagonism and serotonin reuptake inhibition are described, and potentially represent a new generation of antidepressants. Compound 24 displays good affinities for both the NK1 receptor and the serotonin reuptake site (32 and 25 nM, respectively).
- Ryckmans, Thomas,Balancon, Laurent,Berton, Olivier,Genicot, Christophe,Lamberty, Yves,Lallemand, Benedicte,Pasau, Patrick,Pirlot, Nathalie,Quere, Luc,Talaga, Patrice
-
p. 261 - 264
(2007/10/03)
-
- The discovery of [1-(4-Dimethylamino-benzyl)-piperidin-4-yl]-[4-(3,3-dimethylbutyl)-phenyl]-(3-methyl-but-2-enyl)-amine, an N-type Ca+2 channel blocker with oral activity for analgesia
-
Our drug discovery efforts for N-type calcium channel blockers in the 4-piperidinylaniline series led to the discovery of an orally active analgesic agent 26. 1-[4-Dimethylamino-benzyl)-piperidin-4-yl]-[4-(3,3-dimethyl-butyl)-phenyl]-(3-methyl-but-2-enyl)-amine (26) showed high affinity to functionally block N-type calcium channels (IC50=0.7 μM in the IMR32 assay) and exhibited high efficacy in the anti-writhing analgesia test with mice (ED50=12 mg/kg by po and 4 mg/kg by iv). In this report, the rationale for the design, synthesis, biological evaluation, and pharmacokinetics of this series of blockers is described. Copyright (C) 2000 Elsevier Science Ltd.
- Hu, Lain-Yen,Ryder, Todd R.,Rafferty, Michael F.,Taylor, Charles P.,Feng, M. Rose,Kuo, Be-Sheng,Lotarski, Susan M.,Miljanich, George P.,Millerman, Elizabeth,Siebers, Krista M.,Szoke, Balazs G.
-
p. 1203 - 1212
(2007/10/03)
-